ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ANTX / financials
ORMP (33) SION (33) ADAG (25) TRDA (16) ⌘ Pro Terminal β†’

AN2 Therapeutics Inc. (ANTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.35 -3.97% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.31

AN2 Therapeutics Inc. (ANTX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ SELL / AVOID Cap $170.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANTX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ANTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, AN2 Therapeutics Inc. (NASDAQ: ANTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.35 (-3.97% 1D, market cap $170.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ANTX ranks #410 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ANTX compare to ORMP and SION in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ORMP (Oramed Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -7.8%, cap $171.0M) and SION (Sionna Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.3%, cap $175.0M). Among the 5-stock peer group, ANTX leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANTX?
β–Ό

Per ANTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001880438), AN2 Therapeutics Inc. generated $106.7M in revenue (-32.9% YoY), -$35.2M in net income, and -$29.8M in free cash flow against $62.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.31 (-0.90%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (43/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D-
025507510043
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D+
Cash (8)Whales (10)SEC (10)Macro (12)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$8 Bull$4 Base$3 Bear
πŸ“¬ FREE ANTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ANTX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
πŸ” WHY ANTX SCORES 43/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)

FRED Regime Γ— Technicals: 54% of 52W Range β€’ RSI-14 at 54 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+10/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
35
Grade E$4.30-21.6% Next Q
Q2 (-2Q)
38
Grade E$3.37+7.7% Next Q
Q3 (-1Q)
40
Grade D$3.63+19.8% Next Q
Current
43
Grade D-$4.35-6.7% Hist 90D Ξ±
Trajectory: E (35) β†’ D- (43)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ANTX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ANTX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.87) and Max Pain ($4.57) forces dealer call-delta covering toward $7.55.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANTXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œANTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How ANTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$106.7MGross Profit $55.5M (52%)Cost of Sales $51.2MOp Profit $0 (0%)OpEx (R&D/SG&A) $55.5MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $195.0M
FY24
Rev $159.0M
FY25
Rev $106.7M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$106.7M52%-35.7%-$35.2M-$29.8M-45%
FY 2024$159.0M52%-35.7%-$51.3M-$49.3M-45%
FY 2023$195.0M52%-35.7%-$64.7M-$53.3M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANTX)

  • βœ“Walkthrough of ANTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ANTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.31%πŸ“ HORIZONTAL RANGE
2026-11-03O $4.69H $4.69L $4.35C $4.35VOL 284.7K
RES: $6.75SUP: $3.09SMA50: $4.87SMA200: $4.09
$7.57$5.99$4.41$2.83$1.25RES $6.75SUP $3.09$4.352026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ANTX Butterfly Map β†’ + Track ANTX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -32.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANTX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ANTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANTX)

Health Care Rank #410 of 1015 βš”οΈ ORMP vs ANTX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ANTX vs. ORMP, SION, ADAG, TRDA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AN2 Therapeutics Inc. (ANTX) ranks #410 by composite RQD confidence (43/100, grade D-) and #594 by equity capitalization ($170.9M). Within this direct 5-issuer industry benchmark cohort, ANTX leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANTX ACTIVE
AN2 Therapeutics Inc.
D- 43/100 β€” β€” -35.0% -3.97% $170.9M Benchmark Subject
ORMP
Oramed Pharmaceuticals Inc.
E 33/100 β€” 0.7% -7.8% -2.68% $171.0M /ormp-vs-antx β†’
SION
Sionna Therapeutics Inc.
E 33/100 β€” β€” -28.3% -3.62% $175.0M /sion-vs-antx β†’
ADAG
Adagene Inc.
E 25/100 β€” β€” -35.0% -8.76% $165.8M /adag-vs-antx β†’
TRDA
Entrada Therapeutics Inc.
E 16/100 β€” β€” -35.0% +12.68% $176.6M /trda-vs-antx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001880438 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AN2 Therapeutics Inc. (ANTX) reported GAAP revenue of $106.7M (-32.9% vs. FY2024 revenue of $159.0M , and -45.3% cumulative change since FY2023) , GAAP net income of -$35.2M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (+39.4% YoY). On the balance sheet, ANTX closed FY2025 with $62.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $106.7M -$35.2M -$29.8M -$29.8M $62.0M β€”
FY2024 (FY) 2024-12-31 $159.0M -$51.3M -$49.3M -$49.3M $92.1M β€”
FY2023 (FY) 2023-12-31 $195.0M -$64.7M -$53.3M -$53.3M β€” β€”

3. ANTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AN2 Therapeutics Inc. (NASDAQ: ANTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.35 (-3.97% 1D, market cap $170.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ANTX ranks #410 in composite RQD confidence.

How does ANTX compare to ORMP and SION in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ORMP (Oramed Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -7.8%, cap $171.0M) and SION (Sionna Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.3%, cap $175.0M). Among the 5-stock peer group, ANTX leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANTX?

Per ANTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001880438), AN2 Therapeutics Inc. generated $106.7M in revenue (-32.9% YoY), -$35.2M in net income, and -$29.8M in free cash flow against $62.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ANTX last traded at $4.35 (-3.97% on volume of 299,609 shares), positioning the stock -10.68% below its 50-day simple moving average ($4.87) and +6.36% above its 200-day simple moving average ($4.09). Across its 52-week range of $1.00 to $7.19, ANTX sits at the 54.1% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($3.81 to $4.89).

Direct Sub-Reports: ANTX RQD Cockpit ANTX 12M Forecast ANTX Earnings & Move ANTX Dividends & DRIP ANTX Insiders & 13F ANTX Whale Options ANTX Profit Sankey ANTX News & Why
ROARABLE RATING BRIEF β€’ RQD 43/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

ANTX β€” AN2 Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AN2 Therapeutics Inc. (ANTX) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.35 (-3.97% 1D, market capitalization $170.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -16.86%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AN2 Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, . The FY 2023–FY 2025 financials report revenue of β€” in each period, section, so the company is not currently generating reported revenue. β€” for further business detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AN2 Therapeutics Inc. (ANTX) reported $106.7M in annual revenue (up from $159.0M in FY2024, -32.9% YoY) and -$35.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($195.0M revenue, -$64.7M net income) through FY2025, ANTX scaled operating cash flow to -$29.8M and free cash flow to -$29.8M, backed by $62.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -16.86% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $1.00 – $7.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ANTX carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can ANTX sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $106.7M and free cash flow of -$29.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ANTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AN2 Therapeutics Inc. (ANTX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ANTX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANTX Bull vs. Bear Conversation Board β€” What's Your Call at $4.35?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ANTX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $5.53 (+22.1%)
πŸ“Œ Pinned Debate

Net losses narrowed from -$64.7M in FY 2023 to -$35.2M in FY 2025 while institutional flow still scores 13/20 in the RQD rating.

Picked up a starter position in ANTX in my $100K Virtual Cash book at $4.53. Net losses narrowed from -$64.7M in FY 2023 to -$35.2M in FY 2025 while institutional flow still scores 13/20 in the RQD rating.. Trading inside a $0.98–$7.19 52-week range with -16.86% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator πŸ‚ BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.67 (-19.0%)
Spot @ $4.53

ROIC of -35%, FCF yield of -16.86%, and zero reported revenue across three periods leave the business consuming cash with insider convi

Here is the bear case nobody on the bull side wants to address on ANTX: ROIC of -35%, FCF yield of -16.86%, and zero reported revenue across three periods leave the business consuming cash with insider conviction at 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE